Intellia Therapeutics Financial Ratios
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
13.07+0.47 (+3.73%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Intellia Therapeutics ratio analysis
Intellia Therapeutics earned a net margin of -609.9% in FY 2025, up from -896.8% a year earlier. Return on equity reached -61.5%, meaning Intellia Therapeutics generated -0.61 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Intellia Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 14.75 | 20.72 | 74.61 | 51.53 | 253.61 | 52.52 | 0.02 | 19.87 | 26.50 | 17.68 |
| Price / book | 1.49 | 1.38 | 2.58 | 2.17 | 8.06 | 5.78 | 0.00 | 2.18 | 2.30 | 1.39 |
| Gross margin | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating margin | -651.7% | -923.1% | -1,420.5% | -879.0% | -810.4% | -235.5% | -246.8% | -298.6% | -266.3% | -195.2% |
| Net margin | -609.9% | -896.8% | -1,326.5% | -909.8% | -810.5% | -231.5% | -1,100.1% | -280.4% | -258.6% | -192.0% |
| Free cash flow margin | -585.0% | -612.8% | -1,124.9% | -665.5% | -719.4% | -92.2% | -255.3% | -222.2% | -288.6% | 181.7% |
| Return on equity (ROE) | -61.5% | -59.5% | -45.8% | -38.4% | -25.8% | -25.5% | -175.7% | -30.7% | -22.5% | -15.1% |
| Return on assets (ROA) | -49.0% | -43.6% | -37.0% | -31.2% | -20.7% | -19.8% | -141.9% | -24.6% | -18.0% | -10.6% |
| Current ratio | 5.08 | 5.77 | 8.67 | 9.61 | 6.11 | 9.59 | 8.12 | 8.01 | 11.32 | 9.15 |
| Revenue growth | 16.9% | 59.6% | -30.4% | 57.7% | -43.0% | 34.5% | 41.6% | 16.5% | 58.5% | — |